NO2020044I1 - Indakaterolacetat eller indakaterolxinafoat, fortrinnsvis indakaterolacetat, i kombinasjon med mometasonfuroat og glykopyrronium - Google Patents
Indakaterolacetat eller indakaterolxinafoat, fortrinnsvis indakaterolacetat, i kombinasjon med mometasonfuroat og glykopyrroniumInfo
- Publication number
- NO2020044I1 NO2020044I1 NO2020044C NO2020044C NO2020044I1 NO 2020044 I1 NO2020044 I1 NO 2020044I1 NO 2020044 C NO2020044 C NO 2020044C NO 2020044 C NO2020044 C NO 2020044C NO 2020044 I1 NO2020044 I1 NO 2020044I1
- Authority
- NO
- Norway
- Prior art keywords
- indacaterol
- acetate
- glycopyrronium
- combination
- xinafoate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0613158A GB0613158D0 (en) | 2006-06-30 | 2006-06-30 | Organic compounds |
| GB0613156A GB0613156D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
| GB0613160A GB0613160D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
| GB0613159A GB0613159D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
| EP06117129A EP1878722A1 (en) | 2006-07-13 | 2006-07-13 | Quinolinone derivatives and their pharmaceutical compositions |
| PCT/EP2007/056632 WO2008000839A1 (en) | 2006-06-30 | 2007-07-02 | Quinolinone derivatives and their pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2020044I1 true NO2020044I1 (no) | 2020-12-07 |
Family
ID=38610531
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090312A NO341709B1 (no) | 2006-06-30 | 2009-01-20 | Quinolinderivater, fremgangsmåte for fremstilling og deres farmasøytiske sammensetninger, samt anvendelse for behandling av inflammatorisk eller obstruktiv luftveissykdom. |
| NO2020041C NO2020041I1 (no) | 2006-06-30 | 2020-11-23 | Indakaterolacetat eller indakaterolxinafoat i kombinasjon med mometasonfuroat, fortrinnsvis indakaterolacetat i kombinasjon med mometasonfuroat |
| NO2020044C NO2020044I1 (no) | 2006-06-30 | 2020-12-07 | Indakaterolacetat eller indakaterolxinafoat, fortrinnsvis indakaterolacetat, i kombinasjon med mometasonfuroat og glykopyrronium |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20090312A NO341709B1 (no) | 2006-06-30 | 2009-01-20 | Quinolinderivater, fremgangsmåte for fremstilling og deres farmasøytiske sammensetninger, samt anvendelse for behandling av inflammatorisk eller obstruktiv luftveissykdom. |
| NO2020041C NO2020041I1 (no) | 2006-06-30 | 2020-11-23 | Indakaterolacetat eller indakaterolxinafoat i kombinasjon med mometasonfuroat, fortrinnsvis indakaterolacetat i kombinasjon med mometasonfuroat |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8198450B2 (no) |
| EP (1) | EP2044025B1 (no) |
| JP (1) | JP5253392B2 (no) |
| KR (1) | KR101402398B1 (no) |
| CN (1) | CN101479245B (no) |
| AU (1) | AU2007264946B2 (no) |
| BR (1) | BRPI0713951B8 (no) |
| CA (1) | CA2654801C (no) |
| CY (3) | CY1113733T1 (no) |
| DK (1) | DK2044025T3 (no) |
| ES (1) | ES2396987T3 (no) |
| FR (2) | FR20C1054I1 (no) |
| HK (1) | HK1127597A1 (no) |
| HR (1) | HRP20121074T1 (no) |
| HU (2) | HUS2000043I1 (no) |
| IL (1) | IL195796A (no) |
| LT (2) | LTC2044025I2 (no) |
| MA (1) | MA30540B1 (no) |
| MX (1) | MX2008016542A (no) |
| MY (1) | MY150468A (no) |
| NO (3) | NO341709B1 (no) |
| NZ (1) | NZ573292A (no) |
| PL (1) | PL2044025T3 (no) |
| PT (1) | PT2044025E (no) |
| SI (1) | SI2044025T1 (no) |
| WO (1) | WO2008000839A1 (no) |
| ZA (1) | ZA200809948B (no) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001500738A (ja) | 1996-09-17 | 2001-01-23 | カイロン コーポレイション | 細胞内疾患を処置するための組成物および方法 |
| WO2009031011A2 (en) | 2007-09-05 | 2009-03-12 | Pfizer Limited | Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| KR102074543B1 (ko) | 2013-03-14 | 2020-02-06 | 노파르티스 아게 | 분무-블렌딩을 통한 분무-건조 제제의 탈무정형화 |
| US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| WO2017055506A1 (en) | 2015-09-29 | 2017-04-06 | Laboratorios Lesvi, S.L. | Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate |
| CN110724095B (zh) * | 2019-09-12 | 2023-06-09 | 上海方予健康医药科技有限公司 | 一种茚达特罗乙酸盐的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05202301A (ja) * | 1991-08-29 | 1993-08-10 | Yamamoto Chem Inc | ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料 |
| EP0688871A3 (en) * | 1994-06-24 | 1998-07-08 | Quest International B.V. | Preparation of phytosphingosine derivative |
| FR2777279B1 (fr) * | 1998-04-08 | 2004-08-13 | Hoechst Marion Roussel Inc | Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| GB0029562D0 (en) * | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0127430D0 (en) | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| US7417051B2 (en) | 2002-04-12 | 2008-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising betamimetics and a novel anticholinergic |
| US7250426B2 (en) | 2002-11-29 | 2007-07-31 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Tiotropium-containing pharmaceutical combination for inhalation |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| TWI324150B (en) | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
| PE20050211A1 (es) | 2003-04-02 | 2005-04-27 | Novartis Ag | Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas |
| US7745462B2 (en) | 2003-04-04 | 2010-06-29 | Novartis Ag | Quinoline-2-one derivatives for the treatment of airways diseases |
| JP2005343889A (ja) | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| GB0411056D0 (en) * | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| MX2007011600A (es) | 2005-03-21 | 2007-12-07 | Lilly Co Eli | Compuestos de imidazopiridazina. |
| GB0511065D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
-
2007
- 2007-07-02 ES ES07819899T patent/ES2396987T3/es active Active
- 2007-07-02 CN CN2007800244042A patent/CN101479245B/zh active Active
- 2007-07-02 MY MYPI20085146 patent/MY150468A/en unknown
- 2007-07-02 WO PCT/EP2007/056632 patent/WO2008000839A1/en active Application Filing
- 2007-07-02 PL PL07819899T patent/PL2044025T3/pl unknown
- 2007-07-02 NZ NZ573292A patent/NZ573292A/en unknown
- 2007-07-02 DK DK07819899.1T patent/DK2044025T3/da active
- 2007-07-02 SI SI200731103T patent/SI2044025T1/sl unknown
- 2007-07-02 US US12/304,617 patent/US8198450B2/en active Active
- 2007-07-02 KR KR1020087031819A patent/KR101402398B1/ko active IP Right Grant
- 2007-07-02 BR BRPI0713951A patent/BRPI0713951B8/pt active IP Right Grant
- 2007-07-02 CA CA2654801A patent/CA2654801C/en active Active
- 2007-07-02 EP EP07819899A patent/EP2044025B1/en active Active
- 2007-07-02 MX MX2008016542A patent/MX2008016542A/es active IP Right Grant
- 2007-07-02 AU AU2007264946A patent/AU2007264946B2/en active Active
- 2007-07-02 PT PT78198991T patent/PT2044025E/pt unknown
- 2007-07-02 JP JP2009517241A patent/JP5253392B2/ja active Active
-
2008
- 2008-11-24 ZA ZA2008/09948A patent/ZA200809948B/en unknown
- 2008-12-08 IL IL195796A patent/IL195796A/en active IP Right Grant
- 2008-12-30 MA MA31527A patent/MA30540B1/fr unknown
-
2009
- 2009-01-20 NO NO20090312A patent/NO341709B1/no active Protection Beyond IP Right Term
- 2009-07-20 HK HK09106611.7A patent/HK1127597A1/xx unknown
-
2012
- 2012-05-04 US US13/463,978 patent/US20120316142A1/en not_active Abandoned
- 2012-11-29 CY CY20121101169T patent/CY1113733T1/el unknown
- 2012-12-28 HR HRP20121074TT patent/HRP20121074T1/hr unknown
-
2020
- 2020-11-12 FR FR20C1054C patent/FR20C1054I1/fr active Active
- 2020-11-18 HU HUS2000043C patent/HUS2000043I1/hu unknown
- 2020-11-23 NO NO2020041C patent/NO2020041I1/no unknown
- 2020-11-25 LT LTPA2020535C patent/LTC2044025I2/lt unknown
- 2020-11-26 CY CY2020038C patent/CY2020038I1/el unknown
- 2020-12-07 NO NO2020044C patent/NO2020044I1/no unknown
- 2020-12-08 FR FR20C1063C patent/FR20C1063I1/fr active Active
- 2020-12-09 HU HUS2000053C patent/HUS2000053I1/hu unknown
- 2020-12-14 CY CY2020041C patent/CY2020041I2/el unknown
- 2020-12-16 LT LTPA2020538C patent/LTPA2020538I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2020044I1 (no) | Indakaterolacetat eller indakaterolxinafoat, fortrinnsvis indakaterolacetat, i kombinasjon med mometasonfuroat og glykopyrronium | |
| NO2017002I1 (no) | Cobicistat eller farmasøytisk akseptabelt salt derav og atazanavir eller farmasøytisk akseptabelt salt derav, spesielt atazanavirsulfat | |
| DE602006014147D1 (de) | Aroma- und duftstoffzusammensetzung | |
| SE0601155L (sv) | Gas- och vätsketät skyddsdräkt | |
| DK1951885T3 (da) | Fructooligosaccharidfremstilling in situ og saccharosereduktion | |
| BRPI0915299A2 (pt) | poliamida, composição compreendendo tal poliamida e utilização das mesmas | |
| ZA200802078B (en) | Thiazolinones and oxazolinones and their use as PTP1B inhibitors | |
| DK3090748T3 (da) | Sammensætninger, der omfatter nukleotid- og oligonukleotid-prodrugs | |
| DK2134200T3 (da) | Rygeartikler med begrænser og aerosoldanner | |
| DK1894567T3 (da) | Ledsagende farmaceutiske midler og anvendelse deraf | |
| BRPI0810563A2 (pt) | Negro de fumo de estrutura baixa e método de fazer o mesmo | |
| BRPI0809573A8 (pt) | composição, e, método | |
| DK2139452T3 (da) | Topisk polyaphronsammensætning med D-vitamin og corticosteroid | |
| DK2376791T3 (da) | Afstandsindretning og fastgørelsesindretning med afstandsindretning | |
| DK1700598T3 (da) | Antiproliferativ kombinationsterapi med satraplatin eller JM118 og docetaxel | |
| BRPI0917728A2 (pt) | composição, uso da composição, e, método de prevenção da formação de espuma em uma composição | |
| BRPI0814167A2 (pt) | Composição, e, método | |
| BRPI0922233A2 (pt) | compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas. | |
| DK2344523T3 (da) | Gas-kombinationsvacciner og lægemidler | |
| DK2424992T3 (da) | Ny svampeprotease og anvendelse deraf | |
| BRPI0919794A2 (pt) | dispositivo para uso intracorpóreo, e, composto | |
| DE602006020156D1 (de) | Geschmackszusammensetzung oder duftzusammensetzung und geschmacksverbesserungsmittel | |
| BRPI1006996A2 (pt) | composição, método e uso | |
| EP2186999A4 (en) | GUESTURBINE BUCKET AND GAS TURBINE WITH IT | |
| DK2344141T3 (da) | Sammensætning med amlodipin og bisoprolol |